Figure 1.
Kaplan-Meier curve for all 41 patients with NSCLC receiving gefitinib therapy. The (A) PFS and (B) OS in the 41 patients were 9.6 and 22.6 months, respectively. NSCLC, non-small cell lung cancer; PFS, progression-free survival; OS, overall survival.